These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 3056547)

  • 21. Composite tissue allotransplantation in chimeric hosts: part I. Prevention of graft-versus-host disease.
    Gorantla VS; Prabhune KA; Perez-Abadia G; Ildstad ST; Maldonado C; Orhun HI; Majzoub RK; Francois CG; Kakoulidis TP; Brouha PC; Anderson GL; Pidwell DJ; Breidenbach WC; Barker JH
    Transplantation; 2003 Apr; 75(7):922-32. PubMed ID: 12698075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
    Pelot MR; Pearson DA; Swenson K; Zhao G; Sachs J; Yang YG; Sykes M
    Biol Blood Marrow Transplant; 1999; 5(3):133-43. PubMed ID: 10392959
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Leucyl-leucine methyl ester-treated haploidentical donor lymphocyte infusions can mediate graft-versus-leukemia activity with minimal graft-versus-host disease risk.
    Hsieh MH; Varadi G; Flomenberg N; Korngold R
    Biol Blood Marrow Transplant; 2002; 8(6):303-15. PubMed ID: 12108916
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children.
    Rovelli A; Arrigo C; Nesi F; Balduzzi A; Nicolini B; Locasciulli A; Vassallo E; Miniero R; Uderzo C
    Bone Marrow Transplant; 1998 Mar; 21(6):577-81. PubMed ID: 9543061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of cyclosporine-induced syngeneic graft-versus-host disease in bone marrow transplantation by UV-B irradiated bone marrow cells.
    Ohajekwe OA; James T; Hardy MA; Oluwole SF
    Bone Marrow Transplant; 1995 Apr; 15(4):627-32. PubMed ID: 7655391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
    Johnson BD; Drobyski WR; Truitt RL
    Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
    Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of oral tolerance in bone marrow transplantation recipients suppresses graft-versus-host disease in a semiallogeneic mouse model.
    Nagler A; Ohana M; Alper R; Doviner V; Sherman Y; Rabbani E; Engelhardt D; Ilan Y
    Bone Marrow Transplant; 2003 Aug; 32(4):363-9. PubMed ID: 12900772
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonmitogenic anti-CD3F(ab')2 fragments inhibit lethal murine graft-versus-host disease induced across the major histocompatibility barrier.
    Blazar BR; Taylor PA; Snover DC; Bluestone JA; Vallera DA
    J Immunol; 1993 Jan; 150(1):265-77. PubMed ID: 8417127
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
    Russell CA
    Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of transient treatment with FK506 in the early phase on cyclophosphamide-induced bone marrow chimerism and transplant tolerance across MHC barriers.
    Okayama J; Ko S; Kanehiro H; Kanokogi H; Nakajima Y
    J Surg Res; 2006 Jun; 133(2):61-8. PubMed ID: 16376943
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of anti-CD3 epsilon F(ab')2 fragments in vivo to modulate graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC-matched bone marrow transplantation.
    Johnson BD; McCabe C; Hanke CA; Truitt RL
    J Immunol; 1995 May; 154(10):5542-54. PubMed ID: 7730653
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Immunosuppressive drugs in the prevention and treatment of GVHD after allogenic bone marrow transplantation].
    Basić-Jukić N; Labar B
    Acta Med Croatica; 2003; 57(2):131-9. PubMed ID: 12879693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thalidomide--the need for a new clinical evaluation of an old drug.
    Ehninger G; Eger K; Stuhler A; Schuler U
    Bone Marrow Transplant; 1993; 12 Suppl 3():S26-8. PubMed ID: 8124253
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity.
    Sykes M; Abraham VS; Harty MW; Pearson DA
    J Immunol; 1993 Jan; 150(1):197-205. PubMed ID: 8093257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-host cytotoxic T cells of bone marrow transplant recipients with or without graft-versus-host disease are equally sensitive to cyclosporin A.
    Liem LM; van Noort JT; Goulmy E
    Bone Marrow Transplant; 1996 Jul; 18(1):73-8. PubMed ID: 8831998
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amelioration of acute graft-versus-host disease and re-establishment of tolerance by short-term treatment with an anti-TCR antibody.
    Maeda T; Eto M; Lin T; Nishimura Y; Kong YY; Nomoto K; Nomoto K
    J Immunol; 1994 Nov; 153(9):4311-20. PubMed ID: 7930630
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differences between lymphocyte subsets, after allogeneic bone marrow transplantation, in patients who received tacrolimus and patients who received cyclosporin A.
    Fukuda H; Teshima H; Karasuno T; Hiraoka A; Nakamura H; Masaoka T
    Int J Hematol; 2000 Jan; 71(1):70-4. PubMed ID: 10729997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.